Vitrolife

Valuation Analysis

About the Company

Vitrolife en bref

Vitrolife (VITR.ST) is currently trading at 86,10 € with a market capitalization of 10,1 Md €. The 52-week range spans from 84,00 € to 153,50 €; the current price is 43.9% below the yearly high. Year-over-year revenue growth stands at -1.6%.

💰 Dividende

Vitrolife pays an annual dividend of 1,10 € per share, representing a yield of 1.28%. The payout ratio stands at 33.85%.

📊 Avis des analystes

5 analystes évaluent Vitrolife (VITR.ST) au consensus : Achat Fort. L'objectif de cours moyen est de 129,60 €, soit un potentiel de +50.52% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 95,00 € à 155,00 €.

Vitrolife : la thèse d'investissement en détail

Vitrolife (VITR.ST) operates in the Healthcare — specifically Medical Devices — and is headquartered in Sweden. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 28.7% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 59.23% gross margin and 23.1% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Strong Buy with an average price target implying roughly 50.52% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -1.6% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 50.52% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to above-average price swings.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Vitrolife?

Compare top-rated brokers — low fees, trusted providers, fully regulated.